Publicaciones (49) Publicaciones de Hugo Arias Pulido

2024

  1. An Abscopal Effect on Lung Metastases in Canine Mammary Cancer Patients Induced by Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles and Anti-Canine PD-1

    Cells, Vol. 13, Núm. 17

2023

  1. Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Induces Local and Systemic Antitumor Efficacy in Canine Mammary Cancer Patients

    Cells, Vol. 12, Núm. 18

2022

  1. Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

  2. Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes

    Cells, Vol. 11, Núm. 18

2021

  1. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients

    Breast Cancer Research and Treatment, Vol. 190, Núm. 3, pp. 477-489

  2. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance

    Nature Communications, Vol. 12, Núm. 1

2018

  1. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

    Breast Cancer Research and Treatment, Vol. 171, Núm. 2, pp. 273-282

  2. Treatment of Canine Oral Melanoma with Nanotechnology-Based Immunotherapy and Radiation

    Molecular Pharmaceutics, Vol. 15, Núm. 9, pp. 3717-3722

2017

  1. Adaptive immunity programmes in breast cancer

    Immunology, Vol. 150, Núm. 1, pp. 25-34

  2. Comparative aspects of canine and human inflammatory breast cancer

    Seminars in Oncology, Vol. 44, Núm. 4, pp. 288-300

2016

  1. Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/TRAIL-Cisplatin combination therapy in cervical cancer

    Genes Chromosomes and Cancer, Vol. 55, Núm. 2, pp. 177-189

2015

  1. Science and technology consortia in U.S. biomedical research: A paradigm shift in response to unsustainable academic growth

    BioEssays, Vol. 37, Núm. 2, pp. 119-122

2014

  1. Oxygen regulates molecular mechanisms of cancer progression and metastasis

    Cancer and Metastasis Reviews, Vol. 33, Núm. 1, pp. 183-215

2013

  1. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

    Oral Oncology, Vol. 49, Núm. 5, pp. 461-467

2012

  1. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

    BMC Cancer, Vol. 12

  2. DR6 as a diagnostic and predictive biomarker in adult sarcoma

    PLoS ONE, Vol. 7, Núm. 5

  3. Erratum: Alveolar soft-part sarcoma of paranasal sinuses (International Journal of Surgical Pathology (2011) 19:5 DOI: 10.1177/1066896911409575)

    International Journal of Surgical Pathology

  4. Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients

    Breast Cancer Research and Treatment, Vol. 131, Núm. 2, pp. 437-444

  5. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: The axtell regimen

    Annals of Oncology, Vol. 23, Núm. 3, pp. 785-790

  6. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer

    BMC Cancer, Vol. 12